What should you know about erdafitinib for bladder cancer?

It is not a general treatment for every bladder cancer. Testing of tumour tissue, and sometimes other clinical information, helps the oncology team decide whether it is suitable.

Bladder cancer, also called urothelial carcinoma of the bladder, can behave differently from one person to another. Erdafitinib blocks signals linked to certain fibroblast growth factor receptor, or FGFR, changes. These signals can help cancer cells grow, so blocking them may slow or control the disease in people whose tumour has a relevant alteration.

Treatment is usually taken by mouth according to a schedule set by the oncology team. The dose may be adjusted or treatment paused if side effects occur. Monitoring can include blood tests, eye checks, and assessment of phosphate levels, because erdafitinib can affect the eyes, skin, nails, mouth, and mineral balance.

Ask whether your cancer has been tested for an FGFR alteration and how that result affects the treatment choices. Tell the team about eye problems, medicines and supplements, dental concerns, and any kidney or liver condition before starting.

Take the medicine exactly as prescribed and do not change the dose on your own. Report blurred vision, dry or irritated eyes, mouth sores, severe skin or nail changes, unusual thirst, weakness, or new swelling promptly. Keep scheduled blood tests and eye appointments, even when you feel well.

Your team may compare erdafitinib with other options, such as chemotherapy, immunotherapy, surgery, or a clinical trial where appropriate. A cystoscopy or scans may be used to assess the bladder and track the cancer.

Contact your oncology team urgently for a sudden change in vision, eye pain, marked redness, or difficulty seeing. Prompt advice is also needed for severe mouth discomfort that prevents drinking, extensive blistering or peeling skin, heavy bleeding, fever, or repeated vomiting.

Seek emergency help for trouble breathing, fainting, confusion, or inability to pass urine. Difficulty passing urine can require urgent assessment in someone with bladder cancer, particularly when it is accompanied by pain, abdominal swelling, or blood in the urine.

Useful questions include: What FGFR result was found, and what does it mean for me? What earlier treatments have been considered? Which symptoms should make me stop a dose and call? How will my eyes, blood tests, and scans be monitored? What alternatives are available if erdafitinib is not suitable or stops working?